ASX Announcement QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C STAGED PROGRAM TO ADVANCE OVARIAN CANCER TEST TOWARDS US LDT READINESS • An independent US diagnostics expert validated INOVIQ’s OC2200 technical review, confirming pre-analytical sample collection and handling differences as the...
Quarterly Activities Report and Appendix 4C - September 2026
Filed with ASX ·
6ix is reading this filing.
Story so far
Earlier from Inoviq
- INOVIQ Announces Leadership Change
- EXO-OC Technical Review and Commercialisation Pathway
- EXO-OC Study Outcome Investor Webinar Presentation
- Quarterly Activities Report and Appendix 4C - June 2026
- EXO-OC algorithm and clinical study update
Later from Inoviq
All Inoviq news releasesFollow Inoviq into a list and get an email when it puts out news.
Follow Inoviq